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Although the concept of targeted or community-wide treatment
for soil-transmitted helminths (STHs) is not new, having been
initiated originally by the Rockefeller Sanitary Commission in the
United States [1,2] and more recently supported by Warren [3]
and others some 30 years ago as a feasible approach, it is only in
the last 10 years, since the World Health Assembly resolution [4],
that helminth control has become a reality. Today there are a
number of global initiatives, such as the Global Programme for the
Elimination of Filariasis and the Schistosomiasis Control Initiative,
where anthelminthics form a large part of the structure of mass
treatment programmes. In addition, the move towards integrated
programmes and a number of different drug interventions has
meant that, at last, a large portion of the global population at risk
is being treated. This was further augmented in 2010 by additional
large donations from GlaxoSmithKline [5] and Johnson &
Johnson [6], so that in the near future almost one quarter of the
global population may be treated each year with anthelminthics.
However, for the STHs, as for schistosomiasis, these interventions
are based on a very limited drug armamentarium. There is
therefore a very real risk that widespread use may engender drug
resistance and put the programmes at risk. Thus, it is imperative
that active monitoring is undertaken to detect, and hopefully
respond to, the first signs of drug resistance. While the genetic
changes associated with drug resistance to the most widely used
drugs for STHs, the benzimidazole carbamates, albendazole and
mebendazole, are well understood, active screening using genetic
markers is probably impractical other than for confirmation of its
occurrence. Therefore, monitoring of drug efficacy in the field is,
and will probably remain, the tool of choice for the foreseeable
future.
For field monitoring of anthelminthic efficacy, it is essential that
standard protocols are employed that have been tested for their
sensitivity and ease of implementation. Since the benzimidazoles
were introduced for human use some 30 years ago, there have
been many studies, mostly looking at efficacy in single sites on a
single occasion, although the work in Pemba Island, Republic of
Tanzania, has looked at longitudinal changes in efficacy as well
[7]. The problem underlying most of these studies is the lack of a
consistent methodology, a point noted in a Cochrane analysis of
the nutritional and cognitive impacts of anthelminthics [8] and
more recently by Geary et al. [9]. Thus, the paper by Vercruysse
and colleagues in this issue [10] is a welcome attempt at
developing a rational and tested methodology for assessment of
albendazole (and therefore, by inference, anthelminthic) efficacy.
They have opted to use the McMaster technique, which, while
being better for quantitation, is more difficult to use in the field
compared to the more widely used Kato-Katz test. The latter is,
however, only semi-quantitative and needs to be read immediately
to identify hookworm eggs. A change to the McMaster or an
equivalent quantitative technique is necessary if one is hoping to
track alterations in anthelminthic efficacy over time that will
require the more sensitive evidence from egg reduction measures
rather than gross cure rates While cure rates are usually
considered to be a key measure of efficacy, egg reduction is of
greater importance in STH control, because the aim is to reduce
infection, rather than to eliminate it, since high worm burdens are
the cause of morbidity. Therefore, drug failure, as shown in lower
egg reduction rates, will have greater importance in control
approaches, and will occur earlier than poor cure rates. Currently,
however, cure rates will remain the key measure of anthelminthic
efficacy for new drugs, and appropriate thresholds need to be
agreed upon in line with those (cure rates .90%) used for
approval of veterinary medicines. The authors argue that new
efficacy levels need to be agreed to replace those currently
accepted by the World Health Organization [11], but this may
need further study before agreement can be reached.
In establishing the rationale for their study, the authors argue
strongly for numbers that will be statistically sound. Regrettably,
one of the weaknesses in the data is that three countries failed to
reach their overall recruitment goal, and since three countries had
more than one site under study, it is possible that only two
countries exceeded the recruitment goal in terms of site
recruitment. Interestingly, the two worst performing countries
were Brazil and India, where one would expect to be able to find
suitable sites to test efficacy. It also emphasises the problems in
conducting efficacy studies, and recruitment is likely to be an
increasing problem as control programmes become more
widespread. Additionally, since infection rates vary widely, both
globally and locally, it is essential that longitudinal measures of
efficacy be obtained from defined sentinel sites. The level of detail
provided in the paper (district/province/state) is clearly inade-
quate for follow-up, especially when more accurate identifiers such
as global positioning system coordinates are available.
A standard evaluation protocol is a fine goal, but it is unlikely
that the current approach will gain universal acceptance
immediately. The methods will need to be fine tuned, and this
requires at least a repeat of the current study, ensuring that
recruitment numbers are consistent at all sites. For evaluation of
efficacy for a particular helminth, defined thresholds of recruit-
ment should be reached; from the paper by Vercruysse et al. it
appears that 200 individuals per site and species would be
sufficient. Basing such critical evaluations on small numbers is a
Citation: Horton J (2011) A Standardised Protocol for Evaluation of Anthelmin-
thic Efficacy. PLoS Negl Trop Dis 5(3): e1010. doi:10.1371/journal.pntd.0001010
Editor: Simon Brooker, London School of Hygiene & Tropical Medicine, United
Kingdom
Published March 29, 2011
Copyright:  2011 John Horton. This is an open-access article distributed
under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the
original author and source are credited.
Funding: No funding was received for this work.
Competing Interests: The author has declared that no competing interests
exist.
* E-mail: Hedgepigs@aol.com
www.plosntds.org 1 March 2011 | Volume 5 | Issue 3 | e1010concern, especially as findings of reduced efficacy could result in
costly changes in policy or approach.
Finding appropriate locations to use for long-term evaluation is
now a problem, and will become more difficult with time. It is
therefore imperative that the lessons from this study are taken
forward and new studies started to consolidate the approach and
provide the material to argue the case. The main difficulty now
will be convincing the world that there is a single acceptable
approach to testing anthelminthic efficacy, both for public health
monitoring and for drug registration. Unfortunately, scientists are
often very conservative when it comes to changing methods, and it
will require effort on the part of the World Health Organization
and other public health bodies to drive through a standardised
anthelminthic protocol as being essential to long-term public
health goals. To fail to do so will mean that resistance may only be
identified when it is too late, and that will be failing those who
need anthelminthics most.
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